- Home
- BFRI vs PLUR Comparison
BFRI vs PLUR Comparison
Compare BFRI & PLUR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | BFRI | PLUR |
|---|---|---|
| Founded | 1997 | 2001 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 12.2M | 12.5M |
| IPO Year | 2021 | 2026 |
Fundamental Metrics
Financial Performance| Metric | BFRI | PLUR |
|---|---|---|
| Price | $0.82 | $1.24 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 2 | 0 |
| Target Price | ★ $6.00 | N/A |
| AVG Volume (30 Days) | ★ 168.1K | 59.5K |
| Earning Date | 11-16-2026 | 11-16-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 67.70 | 31.46 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $41,705,000.00 | $1,016,000.00 |
| Revenue This Year | $10.65 | $902.46 |
| Revenue Next Year | $15.88 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 11.75 | N/A |
| 52 Week Low | $0.57 | $0.85 |
| 52 Week High | $1.66 | $4.87 |
Technical Indicators
Market Signals| Indicator | BFRI | PLUR |
|---|---|---|
| Relative Strength Index (RSI) | 39.08 | 56.56 |
| Support Level | $0.77 | $0.88 |
| Resistance Level | $0.96 | $1.43 |
| Average True Range (ATR) | 0.06 | 0.15 |
| MACD | 0.02 | 0.03 |
| Stochastic Oscillator | 23.31 | 59.26 |
Price Performance
Historical ComparisonAbout BFRI Biofrontera Inc.
Biofrontera Inc is a United States-based biopharmaceutical company commercializing a portfolio of pharmaceutical products for the treatment of dermatological conditions with a focus on photodynamic therapy. The Company's licensed products, which include Ameluz as well as the BF-RhodoLED and RhodoLED XL lamps (together, the RhodoLED Lamps), are used for the treatment of actinic keratoses (AKs), which are pre-cancerous skin lesions. The company's revenues are derived from within the United States and, therefore, no other geographical segments.
About PLUR Pluri Inc.
Pluri Inc is a biotechnology company engaged in the research, development, and manufacturing of cell-based products, as well as the commercialization of cell therapeutics and related technologies aimed at delivering solutions across a range of industries, including regenerative medicine, immunotherapy, food tech, CDMO, and AgTech. The company uses its 3D cell expansion technology platform to develop placenta-based cell therapy product candidates (PLX-PAD and PLX-R18) for the treatment of inflammatory, muscle injuries, and hematologic conditions. In addition, it offers CDMO services through PluriCDMO, has launched a novel immunotherapy platform, and is engaged in developing cultivated, cell-cultured coffee and meat.